Reboxetine


Selective norepinephrine reuptake inhibitor

A selective NRI marketed in Europe as Edronax for depression but rejected by the FDA for inadequate efficacy.

Abstract

Reboxetine (Edronax; CAS 71620-89-8; molecular formula C19H23NO3; molecular weight 313.39) is a selective norepinephrine reuptake inhibitor approved in Europe (1997) for major depressive disorder. The FDA rejected the compound’s NDA for inadequate efficacy demonstration. The compound is marketed as the racemate; the (S,S)-enantiomer carries the majority of NET inhibition activity. Pharmacokinetics: plasma half-life 13 hours. The compound is sold as a research chemical in jurisdictions where it is not specifically scheduled.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph